Gossamer Bio Inc. has divulged diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer and viral infections.
LG Chem Ltd. has identified macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Chengdu Easton Biopharmaceuticals Co. Ltd. has synthesized oxalamide derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Xinthera Inc. has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease, colitis, pouchitis, gastroenteritis, eosinophilic esophagitis and lung inflammatory disease.
University of Regensburg has described water-soluble FLT3 (FLK2/STK1) inhibitors and their prodrugs reported to be useful for the treatment of acute myeloid leukemia (AML).
Universität Bonn has divulged P2X purinoceptor 4 (P2RX4; P2X4) antagonists reported to be useful as diagnostics and for the treatment of pain, inflammation, cancer, stroke, multiple sclerosis, atherosclerosis and obesity.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
University of Copenhagen has described cyclic peptides acting as postsynaptic density-95 (PSD-95) protein inhibitors reported to be useful for the treatment of neuropathic pain.
RSS